Gamco Investors INC. ET AL Cuts Holdings in Merck & Co., Inc. (NYSE:MRK)

Gamco Investors INC. ET AL reduced its position in Merck & Co., Inc. (NYSE:MRK) by 5.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 67,206 shares of the company’s stock after selling 4,050 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Merck & Co., Inc. were worth $5,657,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Titan Capital Management LLC CA acquired a new position in Merck & Co., Inc. in the second quarter worth about $25,000. LFA Lugano Financial Advisors SA lifted its holdings in Merck & Co., Inc. by 250.0% in the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares during the last quarter. JJJ Advisors Inc. bought a new position in Merck & Co., Inc. in the second quarter worth about $27,000. Cumberland Partners Ltd bought a new position in Merck & Co., Inc. in the second quarter worth about $40,000. Finally, Fusion Family Wealth LLC lifted its holdings in Merck & Co., Inc. by 268.2% in the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares during the last quarter. 74.95% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have issued reports on MRK. Leerink Swann began coverage on shares of Merck & Co., Inc. in a report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 target price on the stock. Credit Suisse Group reissued a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. Svb Leerink began coverage on shares of Merck & Co., Inc. in a report on Friday, August 16th. They issued an “outperform” rating and a $103.00 target price on the stock. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Finally, Mizuho raised their target price on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $95.13.

Shares of MRK traded up $0.73 during mid-day trading on Friday, reaching $83.61. 760,686 shares of the company’s stock traded hands, compared to its average volume of 8,653,409. The business’s 50-day moving average price is $84.03 and its 200-day moving average price is $82.71. The stock has a market capitalization of $212.31 billion, a P/E ratio of 19.26, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. Merck & Co., Inc. has a 12 month low of $70.89 and a 12 month high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.27. The company had revenue of $12.40 billion for the quarter, compared to analysts’ expectations of $11.59 billion. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 earnings per share. Equities research analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: What does a bar chart display?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply